Table 1 Baseline characteristics of the 195 patients.

From: Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease

Factors

n = 195

Age (year)

59 (18–84)

Gender (male)

90 (46.2%)

BMI (kg/m2)

28.5 (18.1–44.9)

Platelets (× 104/mm3)

19.0 (5.1–41.1)

AST (U/L)

55 (18–182)

ALT (U/L)

70 (10–401)

γ-GTP (U/L)

61 (14–391)

Serum albumin (g/dL)

4.0 (2.3–5.2)

eGFR (mL/min/1.73m2)

76 (29–145)

Prothrombin time (%)

94.6 (41.7–138.5)

Total cholesterol (mg/dL)

192 (96–312)

HDL cholesterol (mg/dL)

47 (23–96)

LDL cholesterol (mg/dL)

121 (40–210)

Triglyceride (mg/dL)

127 (42–480)

Plasma glucose (mg/dL)

105 (79–346)

HOMA-IR

3.52 (0.57–40.64)

Hemoglobin A1c (%)

6.2 (3.8–13.2)

Type 2 diabetes mellitus (presence)

78 (40.0%)

Diabetes medication (yes)

64 (82.1%)

Hemoglobin A1c (%)

7.0 (5.2–13.2)

Hypertension (presence)

101 (51.8%)

Smoking (yes)

64 (32.8%)

Max-CIMT (mm)

1.2 (0.4–4.4)

Hyaluronic acid (ng/ml)

54.4 (10.0–3284)

WFA+-M2BP (C.O.I.)

0.93 (0.24–8.30)

FIB-4 index

2.17 (0.32–10.82)

NFS

− 0.45 (− 4.52–7.61)

Liver steatosis (1/2/3)

101 (51.8%)/75 (38.5%)/19 (9.7%)

Liver inflammation (0/1/2/3)

9 (4.6%)/110 (56.4%)/69 (35.4%)/7 (3.6%)

Liver ballooning (0/1/2)

39 (20.0%)/129 (66.2%)/27 (13.8%)

NAFLD activity score (≤ 4/ ≥ 5)

135 (69.2%)/60 (30.8%)

Liver fibrosis stage (F0/F1/F2/F3/F4)

29 (14.9%)/62 (31.8%)/43 (22.1%)/49 (25.1%)/12 (6.2%)

  1. Data are presented as numbers or medians (ranges or percentages).
  2. BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, γ-GTP gamma glutamyl transpeptidase, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, HOMA-IR homeostasis model assessment-insulin resistance, CIMT carotid intima-media thickness, WFA+-M2BP Wisteria floribunda agglutinin positive Mac-2-binding protein, FIB-4 fibrosis-4, NFS NAFLD (nonalcoholic fatty liver disease) fibrosis score.
Back to article page